{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:35:08Z","timestamp":1792697708968,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective observational registry study compared the efficacy of 12-month denosumab or romosozumab treatment in postmenopausal osteoporosis patients. The primary outcome was the change in bone mineral density (BMD) at the lumbar spine. Secondary outcomes included BMD changes at the total hip and femoral neck, changes in bone turnover markers, and adverse events. Propensity score matching was employed to assemble patient groups with similar baseline characteristics. Sixty-nine patients each received either denosumab or romosozumab for 12\u00a0months. The mean 12-month percentage change from baseline in lumbar spine BMD was 7.2% in the denosumab group and 12.5% in the romosozumab group, indicating a significant difference between the groups. The percentage changes in BMD at both the total hip and femoral neck were also significantly higher at 12\u00a0months in the romosozumab group than in the denosumab group. In denosumab patients, bone formation and bone resorption markers were significantly decreased at 6 and 12\u00a0months from baseline. In the romosozumab group, the bone formation marker was significantly increased at 6\u00a0months and then returned to baseline, while the bone resorption marker was significantly decreased at both time points. Adverse events were few and predominantly minor in both groups, with no remarkable difference in the incidence of new vertebral fractures. Romosozumab showed a higher potential for improving BMD than denosumab in this clinical study of postmenopausal osteoporosis patient treatment.<\/jats:p>","DOI":"10.1038\/s41598-021-91248-6","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T10:14:48Z","timestamp":1622715288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Denosumab versus romosozumab for postmenopausal osteoporosis treatment"],"prefix":"10.1038","volume":"11","author":[{"given":"Tomonori","family":"Kobayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"91248_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00198-015-3238-3","volume":"27","author":"CY Chang","year":"2016","unstructured":"Chang, C. Y., Tang, C. H., Chen, K. C., Huang, K. C. & Huang, K. C. The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan. Osteoporos. Int. 27, 665\u2013676. https:\/\/doi.org\/10.1007\/s00198-015-3238-3 (2016).","journal-title":"Osteoporos. Int."},{"key":"91248_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jbmr.5650070413","volume":"7","author":"B Ettinger","year":"1992","unstructured":"Ettinger, B. et al. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 7, 449\u2013456. https:\/\/doi.org\/10.1002\/jbmr.5650070413 (1992).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/BF01625442","volume":"1","author":"PD Ross","year":"1991","unstructured":"Ross, P. D., Ettinger, B., Davis, J. W., Melton, L. J. 3rd. & Wasnich, R. D. Evaluation of adverse health outcomes associated with vertebral fractures. Osteoporos. Int. 1, 134\u2013140. https:\/\/doi.org\/10.1007\/BF01625442 (1991).","journal-title":"Osteoporos. Int."},{"key":"91248_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3039","volume":"32","author":"SR Cummings","year":"2017","unstructured":"Cummings, S. R. et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J. Bone Miner. Res. 32, 3\u201310. https:\/\/doi.org\/10.1002\/jbmr.3039 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.08090110.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown, J. P. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24, 153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.08090110.1359\/jbmr.0809010 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder, B. Z. et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386, 1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5 (2015).","journal-title":"Lancet"},{"key":"91248_CR7","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura, T. et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture intervention randomized placebo controlled trial (DIRECT). J. Clin. Endocrinol. Metab. 99, 2599\u20132607. https:\/\/doi.org\/10.1210\/jc.2013-4175 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"91248_CR8","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina, K. et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140, 115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574 (2020).","journal-title":"Bone"},{"key":"91248_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi, A. et al. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch. Osteoporos. 14, 59. https:\/\/doi.org\/10.1007\/s11657-019-0608-z (2019).","journal-title":"Arch. Osteoporos."},{"key":"91248_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948 (2016).","journal-title":"N. Engl. J. Med."},{"key":"91248_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein, M. L. et al. Change in bone density and reduction in fracture risk: A meta-regression of published trials. J. Bone Miner. Res. 34, 632\u2013642. https:\/\/doi.org\/10.1002\/jbmr.3641 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TA van Geel","year":"2009","unstructured":"van Geel, T. A., van Helden, S., Geusens, P. P., Winkens, B. & Dinant, G. J. Clinical subsequent fractures cluster in time after first fractures. Ann. Rheum. Dis. 68, 99\u2013102. https:\/\/doi.org\/10.1136\/ard.2008.092775 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"91248_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00198-018-4504-y","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis, J. A., Cooper, C., Rizzoli, R. & Reginster, J. Y. Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos. Int. 29, 1505\u20131510. https:\/\/doi.org\/10.1007\/s00198-018-4504-y (2018).","journal-title":"Osteoporos. Int."},{"key":"91248_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0193841X05275596","volume":"29","author":"JK Luellen","year":"2005","unstructured":"Luellen, J. K., Shadish, W. R. & Clark, M. H. Propensity scores: An introduction and experimental test. Eval. Rev. 29, 530\u2013558. https:\/\/doi.org\/10.1177\/0193841X05275596 (2005).","journal-title":"Eval. Rev."},{"key":"91248_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo, H. et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch. Osteoporos. 7, 3\u201320. https:\/\/doi.org\/10.1007\/s11657-012-0109-9 (2012).","journal-title":"Arch. Osteoporos."},{"key":"91248_CR16","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series 843, 1\u2013129 (1994)."},{"key":"91248_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen, S. et al. Diagnostic criteria for primary osteoporosis: Year 2012 revision. J. Bone Miner. Metab. 31, 247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8 (2013).","journal-title":"J. Bone Miner. Metab."},{"key":"91248_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant, H. K., Wu, C. Y., van Kuijk, C. & Nevitt, M. C. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8, 1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915 (1993).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"M Shiraki","year":"2011","unstructured":"Shiraki, M. et al. Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: Rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). J. Bone Miner. Metab. 29, 37\u201343. https:\/\/doi.org\/10.1007\/s00774-010-0188-x (2011).","journal-title":"J. Bone Miner. Metab."},{"key":"91248_CR20","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher, J. C., Genant, H. K., Crans, G. G., Vargas, S. J. & Krege, J. H. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J. Clin. Endocrinol. Metab. 90, 1583\u20131587. https:\/\/doi.org\/10.1210\/jc.2004-0826 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"91248_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00198-006-0127-9","volume":"17","author":"JA Shepherd","year":"2006","unstructured":"Shepherd, J. A. et al. Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos. Int. 17, 1303\u20131308. https:\/\/doi.org\/10.1007\/s00198-006-0127-9 (2006).","journal-title":"Osteoporos. Int."},{"key":"91248_CR22","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen, A. et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res. 20, 1804\u20131812. https:\/\/doi.org\/10.1359\/JBMR.050403 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik, P. J. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J. Bone Miner. Res. 24, 182\u2013195. https:\/\/doi.org\/10.1359\/jbmr.081112 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","volume":"81","author":"MS Ominsky","year":"2015","unstructured":"Ominsky, M. S. et al. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81, 380\u2013391. https:\/\/doi.org\/10.1016\/j.bone.2015.08.007 (2015).","journal-title":"Bone"},{"key":"91248_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","volume":"84","author":"S Taylor","year":"2016","unstructured":"Taylor, S. et al. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84, 148\u2013159. https:\/\/doi.org\/10.1016\/j.bone.2015.12.013 (2016).","journal-title":"Bone"},{"key":"91248_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky, M. S. et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J. Bone Miner. Res. 30, 1280\u20131289. https:\/\/doi.org\/10.1002\/jbmr.2480 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.3350","volume":"33","author":"DW Dempster","year":"2018","unstructured":"Dempster, D. W. et al. Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study. J. Bone Miner. Res. 33, 627\u2013633. https:\/\/doi.org\/10.1002\/jbmr.3350 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"91248_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14656566.2016.1176147","volume":"17","author":"L Gennari","year":"2016","unstructured":"Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R. & Merlotti, D. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin. Pharmacother. 17, 1141\u20131152. https:\/\/doi.org\/10.1080\/14656566.2016.1176147 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"91248_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl, B., Ferrari, S. & Dempster, D. W. Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis. 8, 225\u2013235. https:\/\/doi.org\/10.1177\/1759720X16670154 (2016).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"91248_CR30","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00198-017-3967-6","volume":"28","author":"J Tamaki","year":"2017","unstructured":"Tamaki, J. et al. Total 25-hydroxyvitamin D levels predict fracture risk: Results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos. Int. 28, 1903\u20131913. https:\/\/doi.org\/10.1007\/s00198-017-3967-6 (2017).","journal-title":"Osteoporos. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91248-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:17:18Z","timestamp":1670059038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91248"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91248-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11801"}}